Lucio H Freitas-Junior

List of Publications by Year
in descending order

76 papers	4,586 citations	147801 31 h-index	102487 66 g-index
78 all docs	78 docs citations	78 times ranked	6319 citing authors

#	Article	IF	Citations
1	UV-C (254â€‰nm) lethal doses for SARS-CoV-2. Photodiagnosis and Photodynamic Therapy, 2020, 32, 101995.	2.6	64
2	Non-cytotoxic 1,2,3-triazole tethered fused heterocyclic ring derivatives display Tax protein inhibition and impair HTLV-1 infected cells. Bioorganic and Medicinal Chemistry, 2020, 28, 115746.	3.0	2
3	Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 13, 107-120.	3.4	8
4	A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity. Molecules, 2020, 25, 2551.	3.8	14
5	Biological Properties of a Novel Multifunctional Host Defense Peptide from the Skin Secretion of the Chaco Tree Frog, Boana raniceps. Biomolecules, 2020, 10, 790.	4.0	12
6	Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement. Bioorganic and Medicinal Chemistry, 2019, 27, 115083.	3.0	18
7	Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. Annals of Hepatology, 2019, 18, 816-824.	1.5	33
8	Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection. Tropical Medicine and Infectious Disease, 2019, 4, 82.	2.3	30
9	Expanding the Biological Application of Fluorescent Benzothiadiazole Derivatives: A Phenotypic Screening Strategy for Anthelmintic Drug Discovery Using Caenorhabditis elegans. SLAS Discovery, 2019, 24, 755-765.	2.7	9
10	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discovery, 2019, 24, 346-361.	2.7	18
11	Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening. European Journal of Medicinal Chemistry, 2019, 163, 649-659.	5.5	25
12	From Live Cells to Caenorhabditis elegans: Selective Staining and Quantification of Lipid Structures Using a Fluorescent Hybrid Benzothiadiazole Derivative. ACS Omega, 2018, 3, 3874-3881.	3.5	29
13	Development of a Focused Library of Triazoleâ€Linked Privilegedâ€Structureâ€Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. ChemMedChem, 2018, 13, 678-683.	3.2	12
14	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. European Journal of Medicinal Chemistry, 2018, 146, 423-434.	5.5	27
15	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols. European Journal of Medicinal Chemistry, 2017, 128, 202-212.	5.5	6
16	Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2459-2464.	2.2	23
17	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. European Journal of Medicinal Chemistry, 2017, 126, 1129-1135.	5.5	20
18	A comparative study of warheads for design of cysteine protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5031-5035.	2.2	32

#	Article	IF	Citations
19	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (Tb GAPDH) and Trypanosoma cruzi trypanothione reductase (Tc TR) and display trypanocidal activity. European Journal of Medicinal Chemistry, 2017, 141, 138-148.	5.5	23
20	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega, 2017, 2, 5666-5683.	3.5	24
21	Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity. Molecules, 2017, 22, 426.	3.8	39
22	Design, Synthesis and Structureâ€"Activity Relationships of a Phenotypic Small Library against Protozoan Infections. Proceedings (mdpi), 2017, 1, 648.	0.2	2
23	Hydrocephalus and arthrogryposis in an immunocompetent mouse model of ZIKA teratogeny: A developmental study. PLoS Neglected Tropical Diseases, 2017, 11, e0005363.	3.0	43
24	Discovery of Novel Leishmanicidal Drugs with Potential L-type Calcium Channel Blockage, Designed by Similarity-Based Virtual Screening Approaches. , 2017, , 01-06.		0
25	Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000Research, 2016, 5, 2523.	1.6	60
26	Open drug discovery for the Zika virus. F1000Research, 2016, 5, 150.	1.6	50
27	Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues. European Journal of Medicinal Chemistry, 2016, 121, 553-560.	5.5	27
28	Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors. European Journal of Medicinal Chemistry, 2016, 109, 173-186.	5.5	17
29	Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti-Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties. Antimicrobial Agents and Chemotherapy, 2015, 59, 3645-3647.	3.2	4
30	Synthesis and Evaluation of DNA Based Quantum Dot Fluorescence <I>In Situ</I> Hybridization (FISH) Probe for Telomere Detection. Journal of Nanoscience and Nanotechnology, 2015, 15, 1708-1713.	0.9	2
31	Proteomic-Based Approach To Gain Insight into Reprogramming of THP-1 Cells Exposed to Leishmania donovani over an Early Temporal Window. Infection and Immunity, 2015, 83, 1853-1868.	2.2	46
32	Drug Discovery for Human African Trypanosomiasis: Identification of Novel Scaffolds by the Newly Developed HTS SYBR Green Assay for Trypanosoma brucei. Journal of Biomolecular Screening, 2015, 20, 70-81.	2.6	34
33	Current and Future Chemotherapy for Chagas Disease. Current Medicinal Chemistry, 2015, 22, 4293-4312.	2.4	45
34	In VitroAntiplasmodial Activities and Synergistic Combinations of Differential Solvent Extracts of the Polyherbal Product,Nefang. BioMed Research International, 2014, 2014, 1-10.	1.9	21
35	Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases. Journal of Medicinal Chemistry, 2014, 57, 3126-3139.	6.4	205
36	Synthesis and biological evaluation of 2-acetamidothiophene-3-carboxamide derivatives against Leishmania donovani. MedChemComm, 2014, 5, 142-146.	3.4	5

#	Article	IF	Citations
37	Discovery of Carbohybrid-Based 2-Aminopyrimidine Analogues As a New Class of Rapid-Acting Antimalarial Agents Using Image-Based Cytological Profiling Assay. Journal of Medicinal Chemistry, 2014, 57, 7425-7434.	6.4	31
38	Kinome siRNA screen identifies novel cell-type specific dengue host target genes. Antiviral Research, 2014, 110, 20-30.	4.1	20
39	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi. European Journal of Medicinal Chemistry, 2014, 84, 395-403.	5.5	47
40	Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Scientific Reports, 2014, 4, 4703.	3.3	161
41	An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi. PLoS ONE, 2014, 9, e87188.	2.5	34
42	Chemo-Immunotherapeutic Antimalarials Targeting Isoprenoid Biosynthesis. ACS Medicinal Chemistry Letters, 2013, 4, 423-427.	2.8	35
43	Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites. Experimental Parasitology, 2013, 134, 235-243.	1.2	19
44	Identification of Novel Compounds Inhibiting Chikungunya Virus-Induced Cell Death by High Throughput Screening of a Kinase Inhibitor Library. PLoS Neglected Tropical Diseases, 2013, 7, e2471.	3.0	63
45	High Content Screening of a Kinase-Focused Library Reveals Compounds Broadly-Active against Dengue Viruses. PLoS Neglected Tropical Diseases, 2013, 7, e2073.	3.0	25
46	Amazonian Plant Natural Products: Perspectives for Discovery of New Antimalarial Drug Leads. Molecules, 2013, 18, 9219-9240.	3.8	34
47	Leishmania amazonensis Promastigotes Present Two Distinct Modes of Nucleus and Kinetoplast Segregation during Cell Cycle. PLoS ONE, 2013, 8, e81397.	2.5	30
48	An Image Analysis Algorithm for Malaria Parasite Stage Classification and Viability Quantification. PLoS ONE, 2013, 8, e61812.	2.5	43
49	Transcription Sites Are Developmentally Regulated during the Asexual Cycle of Plasmodium falciparum. PLoS ONE, 2013, 8, e55539.	2.5	3
50	An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages. PLoS Neglected Tropical Diseases, 2012, 6, e1671.	3.0	117
51	Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 11-19.	3.4	214
52	Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4058-4063.	7.1	61
53	An Image-Based Drug Susceptibility Assay Targeting the Placental Sequestration of Plasmodium falciparum-Infected Erythrocytes. PLoS ONE, 2012, 7, e41765.	2.5	1
54	Visual Genome-Wide RNAi Screening to Identify Human Host Factors Required for Trypanosoma cruzi Infection. PLoS ONE, 2011, 6, e19733.	2.5	30

#	Article	IF	Citations
55	Quantum dots: a new tool for anti-malarial drug assays. Malaria Journal, 2011, 10, 118.	2.3	21
56	An Essential Nuclear Protein in Trypanosomes Is a Component of mRNA Transcription/Export Pathway. PLoS ONE, 2011, 6, e20730.	2.5	24
57	A modified fluorescence in situ hybridization protocol for Plasmodium falciparum greatly improves nuclear architecture conservation. Molecular and Biochemical Parasitology, 2010, 173, 48-52.	1.1	4
58	The Leishmania amazonensis TRF (TTAGGG repeat-binding factor) homologue binds and co-localizes with telomeres. BMC Microbiology, 2010, 10, 136.	3.3	18
59	In vitro and in vivo experimental models for drug screening and development for Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 233-238.	1.6	278
60	Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds. PLoS Neglected Tropical Diseases, 2010, 4, e675.	3.0	123
61	Automated Nuclear Analysis of Leishmania major Telomeric Clusters Reveals Changes in Their Organization during the Parasite's Life Cycle. PLoS ONE, 2008, 3, e2313.	2.5	11
62	Leishmania replication protein A-1 binds in vivo single-stranded telomeric DNA. Biochemical and Biophysical Research Communications, 2007, 358, 417-423.	2.1	31
63	Heterochromatin Silencing and Locus Repositioning Linked to Regulation of Virulence Genes in Plasmodium falciparum. Cell, 2005, 121, 13-24.	28.9	412
64	Telomeric Heterochromatin Propagation and Histone Acetylation Control Mutually Exclusive Expression of Antigenic Variation Genes in Malaria Parasites. Cell, 2005, 121, 25-36.	28.9	432
65	Biochemical Characterization of Proline Racemases from the Human Protozoan Parasite Trypanosoma cruzi and Definition of Putative Protein Signatures. Journal of Biological Chemistry, 2003, 278, 15484-15494.	3.4	58
66	A central role for Plasmodiumfalciparum subtelomeric regions in spatial positioning and telomere length regulation. EMBO Journal, 2002, 21, 815-824.	7.8	115
67	A genetic screen for improved plasmid segregation reveals a role for Rep20 in the interaction of Plasmodium falciparum chromosomes. EMBO Journal, 2002, 21, 1231-1239.	7.8	106
68	Plasmodium telomeres: a pathogen's perspective. Current Opinion in Microbiology, 2001, 4, 409-414.	5.1	107
69	The mucin-like glycoprotein super-family of Trypanosoma cruzi: structure and biological roles. Molecular and Biochemical Parasitology, 2001, 114, 143-150.	1.1	172
70	Frequent ectopic recombination of virulence factor genes in telomeric chromosome clusters of P. falciparum. Nature, 2000, 407, 1018-1022.	27.8	497
71	The use of the green fluorescent protein to monitor and improve transfection in Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2000, 111, 235-240.	1.1	32
72	Identification of the telomere in Trypanosoma cruzi reveals highly heterogeneous telomere lengths in different parasite strains. Nucleic Acids Research, 1999, 27, 2451-2456.	14.5	25

#	Article	IF	Citations
73	Expression of trans-Sialidase and 85-kDa Glycoprotein Genes in Trypanosoma cruzi Is Differentially Regulated at the Post-transcriptional Level by Labile Protein Factors. Journal of Biological Chemistry, 1999, 274, 13041-13047.	3.4	50
74	Two distinct groups of mucin-like genes are differentially expressed in the developmental stages of Trypanosoma cruzi1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBankâ„¢, and DDJB databases under the accession numbers AF027869â€“AFO27880.1. Molecular and Biochemical Parasitology, 1998, 93, 101-114.	1.1	32
75	Organization of trans-sialidase genes in Trypanosoma cruzi. Molecular and Biochemical Parasitology, 1996, 77, 115-125.	1.1	26
76	Evaluation of broad-spectrum antiviral compounds against chikungunya infection using a phenotypic screening strategy. F1000Research, 0, 7, 1730.	1.6	2